drugset / Trial / NCT05625022

Lianhua Qingke for the Rehabilitation of Patient With Omicron Infection

NCT05625022 ↗

Phase 4 Unknown 2000 enrolled Qilu Hospital of Shandong University
RandomizedParallel-groupOpen-labelTreatment

Summary

The patients with Omicron infection usually have fever, respiratory symptoms, tachycardia, headache, toothache, muscle soreness, physical decline, and so on, while others are asymptomatic patients. It is urgent to find drugs to improve the long-term rehabilitation of symptomatic patients with Omicron infection and decrease the duration of viral shedding in both symptomatic and asymptomatic patients. This study aims to investigate the efficacy and safety of Lianhua Qingke tablets in patients with Omicron infection. The duration of viral shedding and symptoms will be evaluated. 6-month follow-up will be performed to evaluate the effect of Lianhua Qingke on long-term rehabilitation of all symptoms induced by Omicron infection, as well as infection events.

Timeline

Start
2022-11-01
Primary completion
2023-06-30
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lianhua Qingke tablets Unknown 4 unknown —